Nutrition & Metabolism (Jun 2021)

PS-341 alleviates chronic low-grade inflammation and improves insulin sensitivity through the inhibition of TM4 (UBAC2) degradation

  • Lili Chen,
  • Kuanping Ye,
  • Xiaocheng Feng,
  • Lianxi Li,
  • Qin Li,
  • Ying Huang,
  • Xuanchun Wang,
  • Rumei Li,
  • Cheng Hu,
  • Zhen Yang,
  • Bin Lu,
  • Yehong Yang,
  • Jie Wen,
  • Zhaoyun Zhang,
  • Min He,
  • Qinghua Wang,
  • Wenbai Zhou,
  • Yintao Li,
  • Naijia Liu,
  • Jinya Huang,
  • Qiwei Shen,
  • Qiyuan Yao,
  • Renming Hu

DOI
https://doi.org/10.1186/s12986-021-00579-8
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Background The TM4 (UBAC2) protein, which contains 4 transmembrane domains and one ubiquitin binding domain, is mainly expressed in cell and nuclear membranes. The current research aimed to explore the role of TM4 in metabolic inflammation and to examine whether the ubiquitin–proteasome inhibitor PS-341 could regulate the function of TM4. Methods The metabolic phenotypes of TM4 knockout (KO) mice were studied. We next explored the association between the polymorphisms of TM4 and obesity in a Chinese Han population. TM4 expression in the visceral fat of obese patients who underwent laparoscopic cholecystectomy was also analysed. Finally, the effect of PS-341 on the degradation and function of the TM4 protein was investigated in vivo and in vitro. Results TM4 KO mice developed obesity, hepatosteatosis, hypertension, and glucose intolerance under a high-fat diet. TM4 counterregulated Nur77, IKKβ, and NF-kB both in vivo and in vitro. The TM4 SNP rs147851454 is significantly associated with obesity after adjusting for age and sex (OR 1.606, 95% CI 1.065–2.422 P = 0.023) in 3394 non-diabetic and 1862 type 2 diabetic adults of Han Chinese. TM4 was significantly downregulated in the visceral fat of obese patients. PS-341 induced TM4 expression through inhibition of TM4 degradation in vitro. In db/db mice, PS-341 administration led to downregulation of Nur77/IKKβ/NF-κB expression in visceral fat and liver, and alleviation of hyperglycaemia, hypertension, and glucose intolerance. The hyperinsulinaemic-euglycaemic clamp demonstrated that PS-341 improved the glucose infusion rate and alleviated insulin resistance in db/db mice. Conclusions PS-341 alleviates chronic low-grade inflammation and improves insulin sensitivity through inhibition of TM4 degradation.

Keywords